Glenmark firms up plans for China, Australia and Thailand
This article was originally published in Scrip
Executive Summary
Glenmark Pharmaceuticals expects increased activity in China, Australia and Thailand as it firms up product dossier filing plans in each of the countries. The combined value of the three markets, where Glenmark is currently establishing branch offices, is about $25 billion.